[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-001", "question": "A 26-year-old G2P1 at 30 weeks' gestation presents with new-onset severe occipital headache, visual scotomata, and right upper quadrant pain. BP is 168/108 mmHg, HR 88, reflexes 3+ with 1-2 beats of clonus. Fetal heart tracing is category I. Labs: platelets 86,000/µL, AST 145 U/L, ALT 162 U/L, creatinine 0.9 mg/dL, urine protein/creatinine ratio 0.5. She received 10 mg IV hydralazine in triage 20 minutes ago; current BP is 162/104 mmHg. She desires future fertility and vaginal delivery if safe. What is the most appropriate NEXT step in management?", "options": ["Administer IV labetalol now and plan for induction of labor at 34 weeks", "Initiate magnesium sulfate and proceed with immediate induction of labor", "Initiate magnesium sulfate and administer betamethasone; plan delivery within 24 hours", "Administer additional IV hydralazine and observe; defer delivery until 34 weeks if blood pressure controlled", "Start oral labetalol and discharge with close outpatient follow-up and twice-weekly NSTs"], "answer": "C", "answer_index": 2, "explanation": "She has preeclampsia with severe features and evolving HELLP (thrombocytopenia, RUQ pain, transaminitis) at 30 weeks. For severe features <34 weeks, optimal care is magnesium, corticosteroids, and expedited delivery within 24 hours at a tertiary center, not expectant management. Immediate induction ignores steroid window and maternal stability; outpatient or prolonged expectant management is unsafe given platelets <100,000 and worsening symptoms.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V (Valid). Verdict: The keyed answer C is the correct best answer. Key stem clues: severe preeclampsia with severe features (BP 168/108, platelets 86k, AST/ALT >2× ULN, RUQ pain, visual scotomata, headache, hyperreflexia with clonus) at 30 weeks; persistent severe hypertension despite hydralazine; fetal status reassuring. These findings mandate seizure prophylaxis with magnesium sulfate, corticosteroids for fetal lung maturity, and expedited delivery within 24–48 h. Option C uniquely combines all three evidence-based steps. Alternatives are inferior: A and D propose delayed delivery to 34 weeks, which is unsafe with HELLP; B omits steroids, missing the opportunity to improve neonatal outcomes; E suggests outpatient management, which is contraindicated. No internal contradictions or missing critical details; a single best answer is defensible. Medical accuracy: aligns with ACOG/SMFM guidelines for severe preeclampsia/HELLP <34 weeks. Minimal fix: none required; optionally clarify delivery timing as “within 24–48 hours” to match guideline language, but current wording is acceptable.\",\n\"medical_accuracy_score\":   \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict: The keyed answer C is the correct best answer. Key stem clues: severe preeclampsia with severe features (BP 168/108, platelets 86k, AST/ALT >2× ULN, RUQ pain, visual scotomata, headache, hyperreflexia with clonus) at 30 weeks; persistent severe hypertension despite hydralazine; fetal status reassuring. These findings mandate seizure prophylaxis with magnesium sulfate, corticosteroids for fetal lung maturity, and expedited delivery within 24–48 h. Option C uniquely combines all three evidence-based steps. Alternatives are inferior: A and D propose delayed delivery to 34 weeks, which is unsafe with HELLP; B omits steroids, missing the opportunity to improve neonatal outcomes; E suggests outpatient management, which is contraindicated. No internal contradictions or missing critical details; a single best answer is defensible. Medical accuracy: aligns with ACOG/SMFM guidelines for severe preeclampsia/HELLP <34 weeks. Minimal fix: none required; optionally clarify delivery timing as “within 24–48 hours” to match guideline language, but current wording is acceptable.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-002", "question": "A 58-year-old man with ischemic cardiomyopathy (LVEF 20%), CRT-D in place, and NYHA class III symptoms despite optimal GDMT (sacubitril/valsartan, carvedilol, spironolactone, empagliflozin, loop diuretic) presents with weight gain and dyspnea. BP 104/66 mmHg, HR 72 (biventricular paced), JVP 12 cm, bibasilar crackles, moderate ascites, no peripheral edema. Labs: Na 130 mEq/L, K 4.4, creatinine 1.8 (baseline 1.3), NT-proBNP 12,000 pg/mL. Echo: LVEF 20%, severe functional MR, normal RV size, mildly reduced RV function, PASP 55 mmHg. Right heart cath: RAP 18 mmHg, PCWP 32 mmHg, CI 1.7 L/min/m², SVR 2100 dyn·s/cm⁵. After IV diuresis, he remains hypotensive with CI 1.6. He is INTERMACS profile 4. What is the best definitive next step?", "options": ["Add continuous IV milrinone as palliative inotropic therapy without advanced therapies", "Refer for urgent isolated cardiac transplantation listing status 2 without LVAD bridge", "Evaluate for transcatheter edge-to-edge repair (TEER) of the mitral valve to reduce MR", "Refer for durable LVAD implantation as bridge to transplant or destination therapy", "Implant a percutaneous Impella device as bridge to decision in the ICU"], "answer": "D", "answer_index": 3, "explanation": "He has advanced, stage D HFrEF with persistent low-output symptoms, high filling pressures, and INTERMACS profile 4, making him appropriate for durable LVAD as bridge to transplant or destination. Isolated transplant without LVAD is not ideal given instability; TEER is for less advanced, stable patients. Chronic inotropes or short-term MCS alone are not definitive strategies in a transplant/LVAD candidate.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. This stage D HFrEF patient (LVEF 20%, CI 1.6, PCWP 32 mmHg) has persistent hypoperfusion and congestion despite optimal GDMT and diuresis, with INTERMACS profile 4 indicating need for durable mechanical circulatory support. Key discriminating clues: worsening renal function (creatinine 1.8), hyponatremia (Na 130), high NT-proBNP (12,000), and elevated SVR (2100) confirm advanced low-output HF. Durable LVAD (D) is the definitive Class I recommendation for INTERMACS 4 as bridge to transplant or destination therapy. Alternatives are clearly inferior: A (chronic milrinone) is palliative and increases mortality; B (isolated urgent transplant) is unrealistic given organ availability and current instability; C (TEER) is contraindicated in low-output states with high surgical risk; E (Impella) is temporary support only, not definitive. No internal contradictions or missing critical details. Medical accuracy is excellent and board-relevant, aligning with current INTERMACS and HF guidelines. Fix: None required.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. This stage D HFrEF patient (LVEF 20%, CI 1.6, PCWP 32 mmHg) has persistent hypoperfusion and congestion despite optimal GDMT and diuresis, with INTERMACS profile 4 indicating need for durable mechanical circulatory support. Key discriminating clues: worsening renal function (creatinine 1.8), hyponatremia (Na 130), high NT-proBNP (12,000), and elevated SVR (2100) confirm advanced low-output HF. Durable LVAD (D) is the definitive Class I recommendation for INTERMACS 4 as bridge to transplant or destination therapy. Alternatives are clearly inferior: A (chronic milrinone) is palliative and increases mortality; B (isolated urgent transplant) is unrealistic given organ availability and current instability; C (TEER) is contraindicated in low-output states with high surgical risk; E (Impella) is temporary support only, not definitive. No internal contradictions or missing critical details. Medical accuracy is excellent and board-relevant, aligning with current INTERMACS and HF guidelines. Fix: None required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-003", "question": "A previously healthy 4-year-old boy presents with 10 days of fever to 39.5°C, conjunctival injection without exudate, cracked lips, polymorphous trunk rash, edema and erythema of hands and feet, and cervical lymphadenopathy. Symptoms partially improved after ibuprofen but recur when stopped. Day-10 echocardiogram: diffuse coronary artery ectasia with z-scores 2.3-2.7, mild LV dysfunction (EF 50%), and small pericardial effusion. Labs: WBC 14,000/µL, platelets 520,000/µL, CRP 10 mg/dL, ESR 80 mm/hr, ALT mildly elevated, sterile pyuria. COVID serology and respiratory viral panel are negative. He has not yet received IVIG. What is the most appropriate initial treatment strategy now?", "options": ["Single dose IVIG 2 g/kg plus high-dose aspirin only", "IVIG 2 g/kg, high-dose aspirin, and a single dose of IV methylprednisolone 30 mg/kg", "IVIG 2 g/kg, low-dose aspirin, and infliximab 5 mg/kg", "IVIG 2 g/kg, high-dose aspirin, and anakinra 2 mg/kg/day", "High-dose aspirin alone because presentation is after day 10 of illness"], "answer": "B", "answer_index": 1, "explanation": "He has classic Kawasaki disease with coronary changes and delayed presentation, which confers high risk of IVIG resistance and coronary progression. Current risk-adapted approaches favor adjunctive corticosteroids with IVIG in high-risk patients (coronary involvement and very elevated inflammatory markers), even after day 10. Aspirin monotherapy is inadequate; biologics are reserved for IVIG-resistant disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. The stem describes a 4-year-old with classic high-risk Kawasaki disease: 10 days of fever, complete mucocutaneous features, diffuse coronary artery ectasia (z-scores 2.3–2.7), mild LV dysfunction, and marked inflammation (CRP 10 mg/dL, ESR 80 mm/hr, thrombocytosis 520k/µL). Delayed presentation with coronary involvement mandates IVIG + high-dose aspirin; concurrent very high inflammatory markers and coronary changes identify a patient at very high risk for IVIG resistance, for whom adjunctive IV methylprednisolone (30 mg/kg) is evidence-based and guideline-concordant (RAISE trial, AHA 2017). Keyed answer B is therefore superior to A (no steroids, suboptimal), C/D (biologics reserved for refractory disease), and E (unsafe monotherapy). No logical flaws, contradictions, or underspecification exist; options are mutually exclusive and permit clear discrimination. Medical accuracy is gold-standard and reflects current risk-stratified management. Minimal fix: None required.\",\"medical_accuracy_score\":   \t\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. The stem describes a 4-year-old with classic high-risk Kawasaki disease: 10 days of fever, complete mucocutaneous features, diffuse coronary artery ectasia (z-scores 2.3–2.7), mild LV dysfunction, and marked inflammation (CRP 10 mg/dL, ESR 80 mm/hr, thrombocytosis 520k/µL). Delayed presentation with coronary involvement mandates IVIG + high-dose aspirin; concurrent very high inflammatory markers and coronary changes identify a patient at very high risk for IVIG resistance, for whom adjunctive IV methylprednisolone (30 mg/kg) is evidence-based and guideline-concordant (RAISE trial, AHA 2017). Keyed answer B is therefore superior to A (no steroids, suboptimal), C/D (biologics reserved for refractory disease), and E (unsafe monotherapy). No logical flaws, contradictions, or underspecification exist; options are mutually exclusive and permit clear discrimination. Medical accuracy is gold-standard and reflects current risk-stratified management. Minimal fix: None required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-004", "question": "A 32-year-old woman with mixed connective tissue disease (U1-RNP positive) on mycophenolate mofetil and low-dose prednisone presents with 3 months of progressive exertional dyspnea and near-syncope. Exam: loud P2, right ventricular heave, no crackles, no edema. HR 94, BP 108/68 mmHg, O2 sat 95% on room air. CT chest: no interstitial lung disease, no PE. TTE: normal LV, moderately dilated RV with reduced function, estimated PASP 75 mmHg, no shunt. Right heart cath: mPAP 46 mmHg, PAOP 9 mmHg, CI 2.0 L/min/m², PVR 9 Wood units. Autoantibodies: strong anti-U1-RNP, negative anti-Scl-70. She desires pregnancy within 1-2 years. What is the most appropriate initial advanced therapy strategy for her pulmonary hypertension?", "options": ["Start amlodipine after acute vasoreactivity testing, then titrate based on BP", "Initiate dual oral therapy with ambrisentan and tadalafil", "Initiate triple therapy including IV epoprostenol plus an endothelin receptor antagonist and a PDE-5 inhibitor", "Start inhaled treprostinil monotherapy and observe functional response", "Use riociguat monotherapy given connective tissue disease-associated PAH"], "answer": "C", "answer_index": 2, "explanation": "She has high-risk WHO group 1 CTD-associated PAH (RV dysfunction, mPAP 46, CI 2.0, PVR 9) and plans pregnancy (a major risk), warranting aggressive up-front therapy. Modern guidelines recommend initial triple therapy with parenteral prostacyclin in high-risk PAH patients. CCBs are only for acute vasoreactivity responders; dual or single oral agents are insufficient for this profile.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V. Verdict: The keyed answer (C) is the correct best choice. Key stem clues that drive a unique best answer: (1) High‑risk PAH phenotype: mPAP 46 mmHg, CI 2.0 L/min/m², PVR 9 Wood units, and RV dysfunction on echo; (2) CTD‑associated PAH (U1‑RNP positive, anti‑Scl‑70 negative) without interstitial lung disease or PE; (3) Patient desires pregnancy, which is a major risk factor that mandates aggressive disease control; (4) No evidence of acute vasoreactivity, making calcium‑channel blockers inappropriate. These features align with current ESC/ERS guidelines that recommend initial triple therapy (parenteral prostacyclin + ERA + PDE‑5 inhibitor) for high‑risk PAH. Alternative options are less suitable: amlodipine (A) is only for vasoreactive patients; dual oral therapy (B) is insufficient for high‑risk disease; inhaled treprostinil monotherapy (D) lacks the necessary combination; riociguat monotherapy (E) is not recommended as initial advanced therapy for high‑risk CTD‑PAH. No internal contradictions or missing critical details; the stem provides sufficient information to select a single best answer. Medical accuracy: The answer reflects contemporary guideline‑based management and board‑level expectations. No logical or medical issues identified. Minimal fix: None required.\",\n\"medical_accuracy_score\":  \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: The keyed answer (C) is the correct best choice. Key stem clues that drive a unique best answer: (1) High‑risk PAH phenotype: mPAP 46 mmHg, CI 2.0 L/min/m², PVR 9 Wood units, and RV dysfunction on echo; (2) CTD‑associated PAH (U1‑RNP positive, anti‑Scl‑70 negative) without interstitial lung disease or PE; (3) Patient desires pregnancy, which is a major risk factor that mandates aggressive disease control; (4) No evidence of acute vasoreactivity, making calcium‑channel blockers inappropriate. These features align with current ESC/ERS guidelines that recommend initial triple therapy (parenteral prostacyclin + ERA + PDE‑5 inhibitor) for high‑risk PAH. Alternative options are less suitable: amlodipine (A) is only for vasoreactive patients; dual oral therapy (B) is insufficient for high‑risk disease; inhaled treprostinil monotherapy (D) lacks the necessary combination; riociguat monotherapy (E) is not recommended as initial advanced therapy for high‑risk CTD‑PAH. No internal contradictions or missing critical details; the stem provides sufficient information to select a single best answer. Medical accuracy: The answer reflects contemporary guideline‑based management and board‑level expectations. No logical or medical issues identified. Minimal fix: None required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-005", "question": "A 24-year-old primigravida at 11 weeks presents with severe nausea, non-bloody emesis 10-15 times daily, 4-kg weight loss, orthostatic tachycardia, and inability to keep down oral medications despite pyridoxine/doxylamine and rectal promethazine. She has ketonuria, Na 131 mEq/L, K 2.9 mEq/L, bicarbonate 19 mEq/L, ALT 78 U/L, AST 65 U/L, normal lipase and thyroid function. Ultrasound: single viable intrauterine pregnancy. She requests to avoid hospitalization if possible and is anxious about teratogenic risk. What is the most appropriate next-step pharmacologic management in addition to IV fluids and electrolyte repletion?", "options": ["Start oral ondansetron and allow discharge with close outpatient follow-up", "Begin continuous subcutaneous metoclopramide infusion as an outpatient", "Administer IV ondansetron and admit for parenteral nutrition via PICC line", "Start transdermal scopolamine and oral mirtazapine", "Administer IV chlorpromazine now and transition to scheduled IV ondansetron or metoclopramide in the hospital"], "answer": "E", "answer_index": 4, "explanation": "She has hyperemesis gravidarum with significant volume depletion and electrolyte derangements, requiring inpatient care and parenteral antiemetics. Phenothiazines (e.g., IV chlorpromazine) followed by scheduled IV ondansetron or metoclopramide are evidence-based for refractory hyperemesis. Outpatient oral or SC regimens are inappropriate given inability to tolerate PO; TPN is reserved for failure of intensive antiemetic therapy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). The stem describes severe hyperemesis gravidarum (HG) with orthostatic tachycardia, 4-kg weight loss, ketonuria, hyponatremia, hypokalemia, and failed PO/rectal antiemetics, mandating inpatient care. The question asks for pharmacologic management in addition to IV fluids/electrolytes. Key discriminating clues are severity markers (electrolyte derangements, hemodynamic compromise) and prior treatment failure, which dictate parenteral therapy. The keyed answer (E) correctly identifies immediate IV chlorpromazine followed by scheduled IV ondansetron or metoclopramide in hospital, consistent with ACOG guidelines for severe HG requiring parenteral antiemetics. Alternatives are inferior: A and B inappropriately suggest outpatient management; C prematurely jumps to TPN before adequate antiemetic trial; D offers oral mirtazapine (cannot tolerate PO) and scopolamine (not first-line). No internal contradictions exist, and the clinical severity implicitly requires admission, making E uniquely defensible. Medical accuracy is sound: phenothiazines, ondansetron, and metoclopramide are evidence-based for refractory HG, while TPN is reserved for antiemetic failure. Minor improvement: explicitly state 'admit for IV therapy' in stem to eliminate any setting ambiguity.\",\"medical_accuracy_score\":   \"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). The stem describes severe hyperemesis gravidarum (HG) with orthostatic tachycardia, 4-kg weight loss, ketonuria, hyponatremia, hypokalemia, and failed PO/rectal antiemetics, mandating inpatient care. The question asks for pharmacologic management in addition to IV fluids/electrolytes. Key discriminating clues are severity markers (electrolyte derangements, hemodynamic compromise) and prior treatment failure, which dictate parenteral therapy. The keyed answer (E) correctly identifies immediate IV chlorpromazine followed by scheduled IV ondansetron or metoclopramide in hospital, consistent with ACOG guidelines for severe HG requiring parenteral antiemetics. Alternatives are inferior: A and B inappropriately suggest outpatient management; C prematurely jumps to TPN before adequate antiemetic trial; D offers oral mirtazapine (cannot tolerate PO) and scopolamine (not first-line). No internal contradictions exist, and the clinical severity implicitly requires admission, making E uniquely defensible. Medical accuracy is sound: phenothiazines, ondansetron, and metoclopramide are evidence-based for refractory HG, while TPN is reserved for antiemetic failure. Minor improvement: explicitly state 'admit for IV therapy' in stem to eliminate any setting ambiguity.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-006", "question": "A 17-year-old previously healthy boy is admitted to the ICU with septic shock due to meningococcemia, requiring norepinephrine and mechanical ventilation. On day 4, BP stabilizes and pressors are stopped. Over the next 24 hours, he develops rapidly worsening hypoxemia with PaO2/FiO2 ratio 90, diffuse bilateral infiltrates, and new hemoptysis. Hb drops from 11 to 8 g/dL without obvious bleeding. Platelets are 220,000/µL, PT/INR normal, PTT normal, fibrinogen 400 mg/dL. Urinalysis: 3+ blood, 2+ protein, many dysmorphic RBCs. Creatinine rises from 0.8 to 2.1 mg/dL. ANA negative, ANCA panel negative, complements normal. Bronchoscopy shows diffuse alveolar hemorrhage; cultures pending. What is the most appropriate next step in management?", "options": ["High-dose IV methylprednisolone and IV cyclophosphamide for presumed ANCA-negative pulmonary-renal vasculitis", "Plasmapheresis plus pulse steroids for suspected anti-GBM disease despite negative serology", "Supportive care only, assuming septic coagulopathy-related lung injury", "Kidney biopsy as soon as feasible to guide immunosuppression decisions", "Start rituximab and prednisone for suspected immune-complex GN related to sepsis"], "answer": "D", "answer_index": 3, "explanation": "He has a pulmonary-renal syndrome with DAH and GN but negative ANCA/anti-GBM serologies and preserved platelets/coagulation, making pure septic DIC unlikely. In this critically ill patient, tissue diagnosis is essential before committing to aggressive immunosuppression, especially with negative serologies. Early kidney biopsy best clarifies the etiology; empiric cytotoxic therapy or plasmapheresis without diagnosis carries high risk and may be inappropriate if the lesion is infection-related.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: Underspecified (U). The vignette presents a classic pulmonary-renal syndrome with diffuse alveolar hemorrhage and glomerulonephritis following meningococcemia. Key discriminating features include negative ANCA panel, normal complements, and normal coagulation studies, arguing against septic DIC and most systemic vasculitides. While the keyed answer D (kidney biopsy) is defensible as a tissue diagnosis is required before committing to high-risk immunosuppression in a critically ill patient, the stem fails to specify anti-GBM antibody status—a critical data point in pulmonary-renal syndrome evaluation. The rationale assumes negative anti-GBM serology, but this unstated assumption is required to eliminate option B (plasmapheresis for anti-GBM) and definitively support D as the single best answer. Without this information, one could argue for empiric plasmapheresis if anti-GBM disease were suspected. All other options are clearly inferior: A and E propose immunosuppression without diagnosis, and C inadequately addresses the active immunologic injury pattern. Medical content is otherwise accurate and guideline-concordant. Minimal fix: Add anti-GBM antibody negative to the serology results in the stem.\",\n\"medical_accuracy_score\":   \t\t\t\t  \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t  \"3\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"U\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: Underspecified (U). The vignette presents a classic pulmonary-renal syndrome with diffuse alveolar hemorrhage and glomerulonephritis following meningococcemia. Key discriminating features include negative ANCA panel, normal complements, and normal coagulation studies, arguing against septic DIC and most systemic vasculitides. While the keyed answer D (kidney biopsy) is defensible as a tissue diagnosis is required before committing to high-risk immunosuppression in a critically ill patient, the stem fails to specify anti-GBM antibody status—a critical data point in pulmonary-renal syndrome evaluation. The rationale assumes negative anti-GBM serology, but this unstated assumption is required to eliminate option B (plasmapheresis for anti-GBM) and definitively support D as the single best answer. Without this information, one could argue for empiric plasmapheresis if anti-GBM disease were suspected. All other options are clearly inferior: A and E propose immunosuppression without diagnosis, and C inadequately addresses the active immunologic injury pattern. Medical content is otherwise accurate and guideline-concordant. Minimal fix: Add anti-GBM antibody negative to the serology results in the stem.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-007", "question": "A 6-week-old full-term girl presents with poor feeding, tachypnea, and sweating with feeds. Weight is at the 3rd percentile (previously 40th). Vitals: HR 180, RR 60, BP 70/40 mmHg in all extremities, O2 sat 96% RA. Exam: hepatomegaly, gallop rhythm, 2/6 holosystolic murmur at apex radiating to axilla, no differential pulses. CXR: cardiomegaly, pulmonary overcirculation. Echo: dilated LV with EF 20%, moderate MR, normal coronaries, no coarctation or structural shunt, normal RV function. ECG: sinus tachycardia. Blood and viral studies pending. After starting IV milrinone and diuretics, she stabilizes. What is the MOST appropriate next step in definitive management planning?", "options": ["Discontinue inotropes as soon as EF improves above 35% and transition to oral heart failure therapy only", "Urgently list for heart transplant as status 1A given high mortality of infantile dilated cardiomyopathy", "Begin high-dose IVIG for presumed viral myocarditis and defer consideration of mechanical support", "Evaluate for durable LVAD candidacy as bridge to transplant or recovery", "Schedule elective mitral valve repair to reduce regurgitation and improve LV function"], "answer": "D", "answer_index": 3, "explanation": "She has severe idiopathic/viral dilated cardiomyopathy with EF 20% and inotrope dependence, placing her at high risk of deterioration. Early evaluation for durable LVAD as bridge to transplant or recovery is recommended in infants with advanced heart failure who respond incompletely to medical therapy. Immediate transplant listing without MCS may be risky given wait times; valve surgery will not address primary LV dysfunction; IVIG alone is insufficient as definitive strategy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid). Verdict: Correct best answer. Key stem clues: 6-week-old infant with severe idiopathic/viral dilated cardiomyopathy (EF 20%), inotrope dependence requiring milrinone, and hemodynamic stabilization. These findings place her in INTERMACS profile 2-3, indicating high risk for decompensation and waitlist mortality. The question asks for definitive management planning. Option D (evaluate for durable LVAD) is most appropriate because current pediatric heart failure guidelines recommend early mechanical circulatory support (MCS) evaluation for infants with advanced heart failure who cannot be weaned from inotropes. This serves as bridge to transplant or recovery. Option B (urgent transplant listing) alone is suboptimal given prolonged infant wait times and risk of clinical deterioration without MCS. Options A, C, and E are incorrect: A is premature discontinuation of essential support, C is insufficient monotherapy for severe disease, and E addresses secondary MR rather than primary LV pathology. Minor terminology limitation: 'durable LVAD' is imprecise for infants (paracorporeal VADs are standard), but conceptually accurate per guidelines. No contradictions; options are discriminatory. Minimal fix: Replace 'durable LVAD' with 'mechanical circulatory support (e.g., Berlin Heart EXCOR)' for clarity.\",\"medical_accuracy_score\":   \t\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict: Correct best answer. Key stem clues: 6-week-old infant with severe idiopathic/viral dilated cardiomyopathy (EF 20%), inotrope dependence requiring milrinone, and hemodynamic stabilization. These findings place her in INTERMACS profile 2-3, indicating high risk for decompensation and waitlist mortality. The question asks for definitive management planning. Option D (evaluate for durable LVAD) is most appropriate because current pediatric heart failure guidelines recommend early mechanical circulatory support (MCS) evaluation for infants with advanced heart failure who cannot be weaned from inotropes. This serves as bridge to transplant or recovery. Option B (urgent transplant listing) alone is suboptimal given prolonged infant wait times and risk of clinical deterioration without MCS. Options A, C, and E are incorrect: A is premature discontinuation of essential support, C is insufficient monotherapy for severe disease, and E addresses secondary MR rather than primary LV pathology. Minor terminology limitation: 'durable LVAD' is imprecise for infants (paracorporeal VADs are standard), but conceptually accurate per guidelines. No contradictions; options are discriminatory. Minimal fix: Replace 'durable LVAD' with 'mechanical circulatory support (e.g., Berlin Heart EXCOR)' for clarity.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-008", "question": "A 29-year-old woman at 36+1 weeks with known SLE (class IV lupus nephritis in remission on azathioprine and hydroxychloroquine) presents with 3 days of severe frontal headache, visual blurring, and increasing lower extremity edema. BP 164/102 mmHg (baseline 110/70), HR 92. Labs: platelets 185,000/µL, AST 40 U/L, ALT 35 U/L, creatinine 1.3 mg/dL (baseline 1.1), urine protein/creatinine ratio 2.2 (baseline 1.8), C3 and C4 low, anti-dsDNA titer increased from 1:80 to 1:320, urinalysis with active sediment (RBC casts). Fetus is cephalic, reassuring NST. What is the most appropriate management strategy?", "options": ["Diagnose superimposed preeclampsia with severe features and proceed to immediate delivery", "Increase azathioprine dose and schedule induction at 39 weeks if no further worsening", "Administer IV methylprednisolone for suspected lupus nephritis flare and continue pregnancy with close monitoring", "Start magnesium sulfate and attempt blood pressure control; delay delivery until 37 weeks", "Add IV cyclophosphamide for nephritis flare and plan delivery after disease control"], "answer": "C", "answer_index": 2, "explanation": "She has overlapping features but labs favor SLE flare: rising dsDNA, low complement, active urinary sediment with only mild new proteinuria and preserved platelets/LFTs. At 36 weeks, severe preeclampsia would typically show worsening proteinuria and other end-organ features. Pulse steroids for lupus nephritis flare while continuing pregnancy with close monitoring is appropriate; immediate delivery is not mandatory unless maternal or fetal status deteriorates.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: M (multiple answers defensible); secondary U (underspecified). Verdict: The keyed answer (C) is not uniquely best; option A is also strongly defensible. Key stem clues: severe frontal headache, visual blurring, BP 164/102 meet severe preeclampsia criteria; however, rising anti‑dsDNA, low C3/C4, and RBC casts strongly suggest a lupus nephritis flare. The stem does not resolve which process dominates, nor does it mention antihypertensive therapy, creating ambiguity. Main logical issue: The vignette allows two competing diagnoses (severe superimposed preeclampsia vs lupus flare) without a discriminating feature to force a single management path, so both immediate delivery (A) and high‑dose steroids with expectant management (C) are reasonable. Main medical accuracy issue: The rationale incorrectly states that severe preeclampsia at term must show worsening proteinuria; current guidelines accept neuro‑visual symptoms and severe BP alone as sufficient. Additionally, the answer omits acute blood‑pressure control, which is required for maternal safety. Minimal fix: Add a sentence clarifying that the urinary sediment is definitive for active lupus nephritis and that the neuro‑visual symptoms are attributed to uncontrolled hypertension rather than preeclampsia, or explicitly state that severe preeclampsia has been ruled out by normal platelets and LFTs, making C the clear best choice.\",\n\"medical_accuracy_score\":    \t\t\t\t  \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t \t\t\t\t  \"3\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible); secondary U (underspecified). Verdict: The keyed answer (C) is not uniquely best; option A is also strongly defensible. Key stem clues: severe frontal headache, visual blurring, BP 164/102 meet severe preeclampsia criteria; however, rising anti‑dsDNA, low C3/C4, and RBC casts strongly suggest a lupus nephritis flare. The stem does not resolve which process dominates, nor does it mention antihypertensive therapy, creating ambiguity. Main logical issue: The vignette allows two competing diagnoses (severe superimposed preeclampsia vs lupus flare) without a discriminating feature to force a single management path, so both immediate delivery (A) and high‑dose steroids with expectant management (C) are reasonable. Main medical accuracy issue: The rationale incorrectly states that severe preeclampsia at term must show worsening proteinuria; current guidelines accept neuro‑visual symptoms and severe BP alone as sufficient. Additionally, the answer omits acute blood‑pressure control, which is required for maternal safety. Minimal fix: Add a sentence clarifying that the urinary sediment is definitive for active lupus nephritis and that the neuro‑visual symptoms are attributed to uncontrolled hypertension rather than preeclampsia, or explicitly state that severe preeclampsia has been ruled out by normal platelets and LFTs, making C the clear best choice.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-009", "question": "An intubated 65-year-old woman with severe influenza A pneumonia develops refractory hypoxemia despite lung-protective ventilation (TV 6 mL/kg, PEEP 14 cm H2O, FiO2 0.9) and paralysis. PaO2/FiO2 ratio is 70. She is placed on prone positioning for 16 hours/day with transient improvement but remains PaO2/FiO2 <80. Hemodynamics: MAP 72 mmHg on low-dose norepinephrine, lactate 1.8 mmol/L. No significant comorbidities; BMI 30 kg/m². Family consents to aggressive support. The center has on-site ECMO with experienced team but limited capacity. Which of the following is the most appropriate next step?", "options": ["Increase PEEP to 20 cm H2O and accept permissive hypercapnia before considering ECMO", "Initiate venovenous ECMO now due to refractory severe ARDS despite optimal conventional therapy", "Switch to high-frequency oscillatory ventilation for rescue oxygenation", "Trial inhaled nitric oxide and further proning cycles before deciding on ECMO", "Initiate venoarterial ECMO because of concurrent vasopressor use"], "answer": "B", "answer_index": 1, "explanation": "She has severe ARDS with PaO2/FiO2 <80 despite optimal lung-protective ventilation, high PEEP, paralysis, and proning-meeting criteria for VV-ECMO in an experienced center. Further escalation of ventilator settings or oscillatory ventilation adds risk with limited additional benefit. Low-dose vasopressor does not mandate VA-ECMO; VV-ECMO is appropriate when cardiac function is adequate and shock is not predominant.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V. Verdict: Correct best answer. Key stem clues driving the decision: PaO2/FiO2 ratio persistently <80 despite 16 hours/day prone positioning, lung-protective ventilation with high PEEP (14 cm H2O), paralysis, and FiO2 0.9; hemodynamic stability (MAP 72 mmHg on low-dose norepinephrine, lactate 1.8 mmol/L) indicating preserved cardiac function; availability of experienced ECMO center despite limited capacity; and absence of contraindications. These findings meet criteria for venovenous ECMO in severe ARDS per EOLIA trial and guidelines. The keyed answer (B) is defensible as the unique best next step when conventional rescue measures have failed. Alternative analysis: Option A (increase PEEP further) risks barotrauma without proven benefit at this stage; Option C (HFOV) is discouraged by OSCILLATE/OSCAR trials; Option D (iNO + more proning) offers only transient oxygenation improvement without mortality benefit; Option E (VA-ECMO) is inappropriate without cardiogenic shock. No logical contradictions or missing critical details. Medical accuracy is excellent and current. Minimal fix: None required; item is board-ready.\",\n\"medical_accuracy_score\":   \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. Key stem clues driving the decision: PaO2/FiO2 ratio persistently <80 despite 16 hours/day prone positioning, lung-protective ventilation with high PEEP (14 cm H2O), paralysis, and FiO2 0.9; hemodynamic stability (MAP 72 mmHg on low-dose norepinephrine, lactate 1.8 mmol/L) indicating preserved cardiac function; availability of experienced ECMO center despite limited capacity; and absence of contraindications. These findings meet criteria for venovenous ECMO in severe ARDS per EOLIA trial and guidelines. The keyed answer (B) is defensible as the unique best next step when conventional rescue measures have failed. Alternative analysis: Option A (increase PEEP further) risks barotrauma without proven benefit at this stage; Option C (HFOV) is discouraged by OSCILLATE/OSCAR trials; Option D (iNO + more proning) offers only transient oxygenation improvement without mortality benefit; Option E (VA-ECMO) is inappropriate without cardiogenic shock. No logical contradictions or missing critical details. Medical accuracy is excellent and current. Minimal fix: None required; item is board-ready.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-010", "question": "A 10-year-old boy with a history of intermittent asthma presents with 3 weeks of fever, weight loss, night sweats, and progressive joint pains. Exam: non-blanching palpable purpura on lower extremities, mononeuritis multiplex with foot drop, and hypertension (130/86 mmHg). No asthma exacerbation. Labs: ESR 90 mm/hr, CRP 12 mg/dL, creatinine 1.1 mg/dL, urinalysis with 1+ protein and few RBCs, hepatitis B surface antigen positive, high HBV DNA titer, negative ANCA. CT angiography: multiple microaneurysms in mesenteric and renal arteries. What is the most appropriate initial treatment strategy?", "options": ["High-dose corticosteroids plus cyclophosphamide without antiviral therapy", "Start entecavir and delay immunosuppression until HBV viral load is suppressed", "High-dose corticosteroids plus plasma exchange and antiviral therapy", "Rituximab with low-dose steroids and entecavir prophylaxis", "Plasma exchange and entecavir only, avoiding immunosuppression"], "answer": "C", "answer_index": 2, "explanation": "He has HBV-associated polyarteritis nodosa with medium-vessel aneurysms and high viral load. Management requires control of both vasculitis and viral replication: short-course high-dose steroids with plasma exchange and concurrent antiviral therapy is recommended. Prolonged cyclophosphamide without antivirals worsens HBV; antivirals alone are insufficient in active PAN; rituximab is less established in HBV-PAN.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V. Verdict: Correct best answer. Key stem clues: positive HBV surface antigen with high DNA, negative ANCA, CT angiography showing multiple microaneurysms in mesenteric and renal arteries, systemic symptoms (fever, weight loss, night sweats), mononeuritis multiplex with foot drop, hypertension, mild proteinuria and hematuria. These findings are classic for HBV-associated polyarteritis nodosa (PAN) with severe organ involvement. The most appropriate initial management, per EULAR/ACR and ACR guidelines, is prompt antiviral therapy (e.g., entecavir) to suppress HBV replication, combined with high-dose glucocorticoids to control vasculitis; plasma exchange is recommended for severe disease (e.g., renal involvement, neuropathy, high viral load) to remove immune complexes. Option C exactly matches this regimen. Option A lacks antiviral therapy, risking fatal HBV reactivation. Option B delays immunosuppression, allowing disease progression. Option D uses rituximab, which is not standard for PAN and has limited data in HBV-PAN. Option E omits steroids, which are essential for vasculitis control. Therefore, C is the unique best answer. No logical contradictions; all necessary clinical data are provided. The item accurately reflects current management of HBV-PAN. No changes required.\",\n\"medical_accuracy_score\":  \t \t \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. Key stem clues: positive HBV surface antigen with high DNA, negative ANCA, CT angiography showing multiple microaneurysms in mesenteric and renal arteries, systemic symptoms (fever, weight loss, night sweats), mononeuritis multiplex with foot drop, hypertension, mild proteinuria and hematuria. These findings are classic for HBV-associated polyarteritis nodosa (PAN) with severe organ involvement. The most appropriate initial management, per EULAR/ACR and ACR guidelines, is prompt antiviral therapy (e.g., entecavir) to suppress HBV replication, combined with high-dose glucocorticoids to control vasculitis; plasma exchange is recommended for severe disease (e.g., renal involvement, neuropathy, high viral load) to remove immune complexes. Option C exactly matches this regimen. Option A lacks antiviral therapy, risking fatal HBV reactivation. Option B delays immunosuppression, allowing disease progression. Option D uses rituximab, which is not standard for PAN and has limited data in HBV-PAN. Option E omits steroids, which are essential for vasculitis control. Therefore, C is the unique best answer. No logical contradictions; all necessary clinical data are provided. The item accurately reflects current management of HBV-PAN. No changes required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]